Compare DIOD & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIOD | EWTX |
|---|---|---|
| Founded | 1959 | 2017 |
| Country | United States | United States |
| Employees | 7989 | 127 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | 1995 | 2021 |
| Metric | DIOD | EWTX |
|---|---|---|
| Price | $83.00 | $37.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $153.33 | $52.62 |
| AVG Volume (30 Days) | 449.7K | ★ 1.4M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.53 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.18 | N/A |
| Revenue Next Year | $21.26 | N/A |
| P/E Ratio | $64.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.28 | $14.68 |
| 52 Week High | $125.99 | $48.51 |
| Indicator | DIOD | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 37.07 |
| Support Level | $74.34 | $30.66 |
| Resistance Level | $97.53 | $41.22 |
| Average True Range (ATR) | 3.76 | 1.64 |
| MACD | -1.91 | -0.27 |
| Stochastic Oscillator | 9.06 | 24.19 |
Diodes Inc is a manufacturer and supplier of high-quality application-specific products within the broad discrete, logic, analog, and mixed-signal semiconductor markets. It serves the customer electronics, computing, communications, industrial, and automotive markets. The Company's products include diodes; rectifiers; transistors; MOSFETs; GPP bridges; GPP rectifiers; protection devices; function-specific arrays; single gate logic; amplifiers and comparators; Hall-effect and temperature sensors; and power management devices, including LED drivers, AC-DC converters and controllers, DC-DC switching and linear voltage regulators, voltage references along with special-function devices, such as USB power switches, load switches, voltage supervisors, and motor controllers.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.